NGFR and cystic fibrosis: Excitingly, DOTAP40-Cre transfected ~60% of NGFR+ basal cell populations after treatment (Fig. 4b, Supplementary Fig. 11) This result is very promising and encouraged us further to evaluate the possibility of our delivery system to correct CFTR mutations in the lungs of a G542X CF mouse model.